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ABSTRACT 
BACKGROUND:  Preconditioning might protect he myocardium against ischemia/ 
reperfusion i jury by reducing infarct size and preventing arrhythmias. Dexmedetomidine 
(DEX) is a highly selective (~2-agonist used for sedoanalgesia in daily anesthetic practice. 
The cardioprotective ef}~cts of DEX on infarct size and on the incidence of arrhythmias ob- 
served after regional ischemia/reperfusion injury in vivo have not been reported. 
OBJECT IVE:  The aim of this study was to determine whether DEX exhibits a 
preconditioning effect and reduces infarct size and the incidence and duration of 
arrhythmias in a regional cardiac ischemia/reperfusion model in rats. 
METHODS:  Adult male Sprague-Dawley rats were anesthetized with sodium thio- 
pental and mechanically ventilated (0.9 mL/100 g at 60 strokes/rain) through a cannula 
inserted into the trachea after tracheotomy. Cardiac ischemia was then produced by 
ligating the left main coronary artery for 30 minutes, followed by a reperfusion period 
of 120 minutes. Blood pressure (BP) and heart rate (HR) were monitored and echocar- 
diograms (ECGs) were performed. Arrhythmia was scored based on incidence and dura- 
tion. The animals were randomly divided into 3 groups. The ischemic preconditioning 
(IPC) group underwent 5 minutes of ischemia followed by 5 minutes of reperfusion before 
the 30-minute ischemia/120-minute reperfusion period. In the DEX group, intraperi- 
toneal (IP) DEX 1 mL (100 pg/kg) was administered 30 minutes before the ischemia/ 
reperfusion period. In the control group, IP saline 1 mL was administered 30 minutes 
before the ischemia/reperfusion period. After reperfusion, the heart was excised, demar- 
cated with saline and ethanol to identify the occluded and nonoccluded myocardium, 
and cut into slices ~2 mm thick, that -were then stained and placed between 2 glass 
plates. The risk zone and the infarct zone were compared between groups. The investi- 
gator assessing the infarcts was blinded to the study group. 
RFSULTS:  Twenty-one adult (aged 4 6 months) male Sprague-Dawley rats 
weighing 280 to 360 g were included in the study; 7 rats were assigned to each group. 
BP, HR, and ECG readings were not significantly different between groups and did not 
change during the study. Arrythmias occurred uring ischemia nd reperfusion in all 
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groups. The duration of the arrhythmias was significantly shorter and the arrhythmia 
score was significantly lower in the 1PC group (all, P < 0.05), compared with the control 
group; however, they were not significantly- different in the DEX group. During the 
ischemic period, duration of ventricular tachycardia (VT) and ventricular premature 
contractions (VPC) in the DEX group was significantly longer than that observed in 
the IPC group (all, P < 0.05). The duration of VPC was also significantly shorter than 
that observed in the control group (both, P < 0.05). Duration of VT during the reperfu- 
sion period in the DEX group was significantly longer than that observed in both IPC 
and control groups (both, P < 0.05). The mean (SD) percentage ofdamage was signifi- 
cantly lower in the IPC group (44.1% [2.0%]) and the DEX group (26.7% [2.0%]) 
compared with the control group (69.0% [3.0%]; both, P < 0.05). The percentage of
damage in the DEX group was also significantly lower compared with the IPC group 
(P < 0.05). 
CONCLUSIONS:  This small, experimental in vivo study found that DEX was 
associated with reduced infarct size in ischemia/reperfusion injury in regional ischemia 
in this rat model but had no effect on the incidence of arrhythmias. Future studies are 
needed to clarify these findings. (Cuff Ther Res C/fn Exp. 2008;69:150 158) © 2008 
Excerpta Medica Inc. 
KEY WORDS:  dexmedetomidine, preconditioning, cardiac ischemia/reperfusion. 
INTRODUCTION 
Ischemia and subsequent reperfusion cause morphologic and functional damage that 
manifest as ventricular arrhythmias within minutes of the occlusion of related arteries. 
A short ischemic period, called/gfecofIditioeei~g, before ischemia and reperfusion may 
protect he myocardium by reducing infarct size and preventing arrhythmias. 1 3 This 
preconditioning effect may also be achieved pharmacologically b  perfusing certain 
drugs before and during ischemia. A number of drugs used in daily- anesthetic practice 
(eg, volatile anesthetics, 4 nitrates, 5 opioids, 6,7 and levosimendan s) have been found to 
produce preconditioning effects. Dexmedetomidine (DEX) is a selective c~2-agonist 
indicated for sedoanalgesia n daily anesthetic practice, especially in intensive care 
units. 9DEX has a broad spectrum of action in hmnans, including sedation, anesthetic- 
sparing effects, analgesia, and decreased heart rate and blood pressure. 
As the outcome after ischemia nd reperfusion is mainly affected by infarct size and 
is manifested as arrhythmias in the early period within minutes, most studies of pre- 
conditioning assess the occurrence of arrhythmias and infarct size) 3 Few studies of the 
cardioprotective effbct of DEX in ischemia/reperfusion injury have been done. l° 12 One 
double-blind, randomized, ose-escalation trial ° performed in 24 patients undergoing 
open-heart surgery found a beneficial effect a decrease in the incidence of adverse 
cardiac events (eg, hemodynamic instability) of DEX (2.30 9.87 g/kg) on ischemic myo- 
cardium when used 1 hour preoperatively, perioperatively, and 48 hours postoperatively. 
An in vivo study H found the beneficial effect of sympatholysis produced by DEX dur- 
ing ischemia/reperfusion n dogs. An in vitro study 12 of the cardioprotective effects of 
DEX (1 and 10 nM) in isolated hearts of rats undergoing lobal ischemia/reperfusion 
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injury reported a significant reduction in coronary flow and significantly decreased 
infarct size. 
The protective ffects of DEX on infarct size and on the incidence of arrhythmias ob- 
served after regional ischemia/reperfusion using an in vivo model have not been reported. 
The aim of this study was to determine whether DEX* exhibits a preconditioning effbct 
and reduces infarct size and the incidence and duration of arrhythmias in an experimen- 
tal regional cardiac ischemia/reperfusion nmdel. 
MATERIALS  AND METHODS 
ANIMALS 
Male Sprague-Dawley rats were used in the study. The rats were obtained from the 
Medical Laboratory Research Institute of Istanbul Universit B Istanbul, Turkey. The 
animals were housed in individual cages in an animal room (temperature 22°C, hmnidity 
40%~0%) on a 12-hour light/dark cycle and were fed standard pellet food (210 kcal/ 
100 g . d l) and water ad libitum after approval by the ethics committee of Abant Izzet 
Baysal University Medical School (Bolu, Turkey). The animals were kept and treated and 
the experiments were carried out in adherence with conditions delineated in the guide- 
lines and recommendations of the S~?brld Medical Association) 3 
EXPERIMENTAL  PROTOCOL 
The animals were randomly divided into 3 groups (Figure 1). Randomization was 
achieved using a computer-based random number generation technique. The animals 
were anesthetized with intraperitoneal (IP) sodium thiopental 50 mg/kg and mechani- 
cally ventilated (0.9 mL/100 g at 60 strokes/rain) through a cannula inserted into the 
trachea fter tracheotomy. Blood pressure was continuously monitored through a can- 
nula inserted into the left carotid artery. Needles inserted subcutaneously- into the 
anterior thorax were used for the echocardiogram (ECG) (lead II) (AD Instruments, 
Oxfordshire, United Kingdom). 
The heart was exposed after opening the chest at the fourth intercostal space, and a 
loose loop of atramnatic silk (5/0) was placed around the left main coronary artery -2 mm 
distally from its origin for ligation during the ischemia period. In all 3 groups, cardiac 
ischemia was induced by ligation of the left main coronary artery with the previously 
placed silk loop for 30 minutes. The silk loop was then loosened to allow reperfusion 
for 120 minutes. 
In the ischemic preconditioning (IPC) group, the rats underwent a 5-minute ischemia 
period followed by a 5-minute reperfhsion period beginning 20 minutes after the anes- 
thetic was administered. The animals in this group then underwent the 30-minute 
ischemia/120-minute reperfusion period. In the DEX group, 1 niL of a solution contain- 
ing DEX 100 pg/kg was administered IP 30 minutes before the ischemia/reperfusion 
period. In the control group, IP saline 1 mL was administered 30 minutes before the 
ischemia/reperfusion period. After completion of the ischemia/reperfusion protocols, animals 
were heparinized and the heart was excised to assess infarction. 
*Trademark: Precedex ® (Abbott Laboratories, Abbott Park, Illinois). 
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Anesthesia 
Initiated 
(sodium thiopental 50 mg/kg) 
Ischemia Reperfusion 
IP DEX 
DEX Group 
(n=7)  • 30min  - -  120min  
Ischemia Ischemia Reperfusion 
IPC Group 
(n = 7) ~ 20 min 5 min - 120  min 
Reperfusion 
Ischemia Reperfusion 
Saline 
Control Group 
(n = 7) • 30 min 120 min 
Figure 1 .  Study protocol. DEX = dexmedetomidine;  IP = intraperitoneal; IPC = i schemic  
precondi t ion ing.  
AR IRHYTHMIA  ANALYS IS  
Heart rate and the duration of arrhythmia were determined using ECG. The inci- 
dence of arrhythmia was analyzed (by one of the authors [O.B.] who was blinded to 
the group to which the animals were assigned) in accordance with the Lambeth 
Conventions 14as ventricular premature contractions, ventricular fibrillation (VF), ven- 
tricular tachycardia, nd other types of arrhythmias (extrasystole, bigeminy, and salvo). 
An arrhythmia score was determined using the following scale15:0 no arrhythmia; 
1 arrhythmia duration <10 seconds; 2 duration 11 to 30 seconds; 3 duration 31 to 
90 seconds; 4 duration 91 to 180 seconds or reversible VF for <10 seconds; 5 dura- 
tion >180 seconds or reversible VF >10 seconds; and 6 irreversible VF or death. These 
scores were used to assess the arrhythmias and to make between-group comparisons. 
DETERMINAT ION OF  INFARCTED AREA 
At the end of the experiment, he left coronary artery was retightened and the heart 
was retrogradely exposed to 10 mL of saline solution and then washed out with 2 mL 
of ethanol administered from the aorta to demarcate the occluded and nonoccluded 
myocardium. 1~Subsequently, hearts were cut into slices -2 mm thick parallel to the 
atrioventricular g oove. The slices were then stained with 0.1% nitroblue tetrazolium in 
phosphate buffer for 20 minutes and placed in formaldehyde solution for 20 minutes. 
The slices were placed between 2 glass plates. The risk zone and the infarct zone were 
traced on acetate sheets from these plates. These pictures were digitalized using a digi- 
tal camera, and areas of infarction were measured using an image-editing software 
program (Adobe Photoshop, Adobe Systems Inc., San Jose, California) by an expert 
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blinded to the study group. The infarct area was divided by the risk zone to calculate 
the percentage of damage. 
STAT IST ICAL  ANALYS IS  
All statistical analyses were performed using SPSS for Windows version 9.0 (SPSS 
Inc., Chicago, Illinois). Parameters were expressed as mean (SEM). The significance of 
the data obtained was evaluated using analysis of variance. The Mann-~hitney U test 
was used to compare the groups. The arrhythmia incidence and scores were compared 
using the Z 2 test. P < 0.05 was considered to be statistically significant. 
RESULTS 
Twenty-one male Sprague-Dawley rats (aged 4 6 months; weight range, 280 360 g) 
were included in the study; 7 rats were assigned to each group. 
Heart rate and blood pressure were similar in all 3 groups before ischemia/reper~sion. 
Heart rate did not change significantly during ischemia or reperfusion in a W group. In 
all groups, arterial blood pressure &creased sharply after ligation and increased slowly 
during reperfusion; the changes were similar between the groups ('Fable I). 
Arrhythmias occurred during ischemia and reperfusion in all groups. The mean 
total duration of arrhythmias was significantly shorter during Jschemia nd reperfusion 
and the arrhythmia scores were significantly lower in the IPC group compared with the 
control group (all, P < 0.05). During the ischemic period, the duration of ventricular 
tachycardia (VT) in the DEX group was significantly greater than that observed in the 
IPC group or the control group (both, P < 0.05). The duration ofventricular premature 
contractions during ischemia in the DEX group was significantly greater than that 
observed in the IPC group and less than that observed in the control group (both, P < 
0.05). During the reperfusion period, duration of VT in the DEX group was greater 
than both the 1PC and control groups (both, P < 0.05). The changes in the duration of 
arrhythmias in the DEX group were not significantly different compared with the con- 
trol group. During ischemia, the arrhythmia score was significantly lower in the IPC 
group compared with the DEX group and the control group (0.33 [0.33] vs 1.66 [0.66] 
and 1.75 [0.47]; both, P < 0.05). During reperfusion, the arrhythmia score was also 
Table I. Hemodynamic changes before ischemia and during ischemia and reperfusion in 
adult male Sprague-Dawley rats (N = 21) ,*  Data are mean (SEM). 
Heart Rate, bpm Blood Pressure, mm Hg 
Before During During Before During During 
Group Ischemia Ischemia Reperfusion Ischemia Ischemia Reperfusion 
IPC 319 (9) 321 (7) 323 (10) 108 (6) 102 (4) 114 (7) 
DEX 334 (12) 326 (8) 332 (12) 116 (5) 103 (5) 119 (8) 
Control 338 (11) 311 (9) 341 (13) 104 (3) 96 (2) 110 (4) 
IPC = ischemic preconditioning; DEX = dexmedetomidine. 
*There were no significant between-group differences. 
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significantly lower in the IPC group compared with the DEX group and the control 
group (0.33 [0.33] vs 2.6 [1.33] and 2.55 [1.47]; both, P < 0.05) (Table II). 
The mean size of the occluded area was similar in the IPC group (44.65 [3.3] ram2), 
DEX group (46.47 [2.7] mm2), and control group (37.42 [3.7] mm2). The infarct area 
was significantly smaller in the DEX group compared with the IPC group and the 
control group (12.41 [2.5] mm 2 vs 19.71 [3.2] mm 2 and 25.83 [2.8] ram2; both, P < 
0.05). The mean (SD) percentage of damage was significantly- lower in the IPC group 
(44.1% [2.0%]) and the DEX group (26.7/% [2.0%]) compared with the control group 
(69.0% [3.0%]; both, P < 0.05). The percentage ofdamage in the DEX group was also 
significantly lower compared with the IPC group (P < 0.05) (Figure 2). 
D|SCUSS|ON 
DEX is used for sedoanalgesia in intensive care units, in postoperative anesthetic care 
units, and in operating rooms during the perioperative period, especially for hemo- 
dynamic stabilization) 2,17 Myocardial ischemia may occur in all of these situations. 
Mangano et a118 reported that myocardial ischemia is one of the most important risk 
factors for adverse cardiac outcome in surgical patients with coronary artery disease. 
This adverse outcome was reported to be reduced by perioperative infusion of DEX) 8 
The mechanism by which DEX decreases myocardial ischemia was thought o be related 
to the sympatholytic effect of the drug. 11,19 Okada et a112 also reported the cardioprotec- 
tive ef~-ct of DEX to be mediated by (z2-adrenergic stimulation. Dahmani et a117 inves- 
tigated the possible mechanism of the preconditioning effect of DEX on cerebral focal 
ischemia and reported that increased phosphorylation of focal adhesion kinase via 
stimulation of c~2-receptors and decreased cleaved caspase-3 expression was significantly 
correlated with cell survival. DEX was also associated with significantly decreasing the 
infarct size in our study, but it did not decrease the incidence of arrhythmias. Similarly, 
hemodynamic changes did not support he differences in the percentage ofdamage, as 
no differences were found between groups in heart rate or blood pressure. We may 
speculate from these results that c~2-adrenergic stimulation using DEX may not totally 
block the factors that cause arrhythmia, although it may prevent ischemia/reperfusion 
injury. A decrease in adrenaline concentration caused by c~2-adrenergic stimulation 
might have been associated with the arrhythmia observed in the DEX group. This 
theory is supported by the study of Bozdogan et al, 15 in which the exogenous adminis- 
tration of adrenaline decreased the occurrence of arrhythmia in an ischemia/reperfusion 
model in rats. Therefore, the decrease in infarct size in the DEX group might be related 
to factors other than adrenaline. Hemodynamic stabilization during ischemia may also 
be related to the cardioprotective and sympatholytic effects of DEX that were observed 
via c~2-adrenergic stimulation. 
The cardioprotective effect of DEX was reported to be related to a decrease in myo- 
cardial oxygen demand, which was attributed to hemodynamic effects (eg, reduction in 
heart rate and preservation of blood flow in ischemic myocardium). 11 The preservation 
of blood flow in ischemic myocardium by o~2-agonists is thought o be caused by local 
metabolic stimuli that prevent adrenergic vasoconstriction during ischemia) 1 DEX use 
has been associated with several simultaneous hemodynamic effects a central sym- 
155 
CURRENT THERAPEUTIC  RESEARCH 
II 
Z 
,_~ 
,_~ 
~.- 
0 
ODZ 
~~ 
~C3 
o t::~0 
d::] [D 
09 09 09 '~  
~ cO (D kO 
¢ Q O,] LO ,
Od O (N 
¢ o o d 
o CO (.O LO 
s.., ~" 8" 
Oq r,..O Ob 
d ~d c4 
~ O 
O4 kO cO 
o o d ~ D... 
> C~ qO CO 
CO CO 
d 4 c4 
~.. c0 00 cO 
N N 0q. 
~ O 
> O O O 
k-- co o d 
> 
LO C~ C~ 
• :H L~ 0 
o d d ~ 
> 0,1 qO L~ 
,-q ~ 02. 
00 
d b,~ ~ b',,- 
Z 
o ox  
8 _aS  
II ~q 
x 
~q'LL 
O @ 
~:  © il 
© II @ 
2 c0~ 
- 8 
~ O 
@ 
>, o100 
"- (2,-0 
Em~ d_ 
o ~ 
Eo ° o 
.£:: ,~.,.4 .~@ @ ~v 
~ . ~ ~  
~'~OOO 
ddd 
~ '~'-I V V v 
156 
H.  KOCOGLU ET  AL .  
Figure 2, 
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Mean (SEM) percentage of infarction by group in male Sprague-Dawley rats 
undergoing ischemia and reperfusion (N = 21). iPC = ischemic preconditioning; 
DEX = dexmedetomidine. *P < 0.05 versus the control group; tp < 0,05 versus 
the IPC group, 
patholytic effect that might reduce blood pressure and a peripheral vasoconstrictive 
effect that might increase blood pressure. Okada et a112 used an isolated heart model to 
investigate the local effects of DEX on the heart. We used an in vivo model to attempt 
to avoid underestimating the systemic effects of DEX on the cardiovascular system. 
L IMITAT IONS 
One of the limitations of this study was not measuring adrenaline concentration, a 
mediator of ischemic preconditioning. We could not clearly explain the conflicting data 
between the occurrence of arrhythmias and the decrease in infarct size in this rat model. 
Although it is clear that DEX was associated with reduced infarct size and protection 
of the heart against ischemia/reperfusion njury, we expected these effects to be sup- 
ported by a decrease in arrhythmias. Further studies are needed to examine these con- 
flicting data and to investigate the applicability of these results to humans. 
CONCLUSIONS 
This small, experimental in vivo study found that DEX was associated with reduced 
infarct size in ischemia/reperfusion njury in regional ischemia in this rat model but had 
no effect on the incidence of axrhythmias. Future studies are needed to clarify- these findings. 
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